Exclusive License AgreementIf ST-403 program is successful, the company stated in the NR today that "its commercial potential is significant..." PAS is also working on B-cell targeted antibody for acute lymphoblastic leukemia stated in today's NR .... looks like sell on news right now, trading at 0.45 but the future looks positive for this stock ... GLTA